Pavel Trunecka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Pavel Trunecka has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Julius Spicak
Institute for Clinical and Experimental Medicine, Prague, Czech Republic
11 shared publications - Sona Frankova
Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
6 shared publications - Eva Honsova
Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
4 shared publications - Jan Sperl
Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
4 shared publications - Martin Oliverius
Department of Surgery, University Hospital Kralovske Vinohrady, Prague, Czech Republic
4 shared publications - Milan Jirsa
Institute for Clinical & Experimental Medicine (IKEM), Prague, 14021, Czech Republic
4 shared publications
Latest Publications
- Open Access
- 15 September 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (9) , 625
Lipid Profile and Hepatic Fat Content Measured by 1H MR Spectroscopy in Patients before and after Liver Transplantation
Increased hepatic fat content (HFC) is a hallmark of non-alcoholic fatty liver (NAFL) disease, a common condition in liver transplant recipients. Proton MR spectroscopy (1H MRS) and MR imaging-based proton density fat fraction as the only diagnosis modality enable precise non-invasive measurement of HFC and, also, fatty acid profiles in vivo. Using 1H MRS at 3T, we examined 47 liver transplantation candidates and 101 liver graft recipients. A point-resolved spectroscopy sequence was used to calculate the steatosis grade along with the saturated, unsaturated and polyunsaturated fractions of fatty acids in the liver. The steatosis grade measured by MRS was compared with the histological steatosis grade. HFC, represented by fat fraction values, is adept at distinguishing non-alcoholic steatohepatitis (NASH), NAFL and non-steatotic liver transplant patients. Relative hepatic lipid saturation increases while unsaturation decreases in response to increased HFC. Additionally, relative hepatic lipid saturation increases while unsaturation and polyunsaturation both decrease in liver recipients with histologically proven post-transplant NASH or NAFL compared to non-steatotic patients. HFC, measured by in vivo 1H MRS, correlated well with histological results. 1H MRS is a simple and fast method for in vivo analysis of HFC and its composition. It provides non-invasive support for NAFL and NASH diagnoses.
- 15 September 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (9) , 625
Open AccessLipid Profile and Hepatic Fat Content Measured by 1H MR Spectroscopy in Patients before and after Liver Transplantation
Increased hepatic fat content (HFC) is a hallmark of non-alcoholic fatty liver (NAFL) disease, a common condition in liver transplant recipients. Proton MR spectroscopy (1H MRS) and MR imaging-based proton density fat fraction as the only diagnosis modality enable precise non-invasive measurement of HFC and, also, fatty acid profiles in vivo. Using 1H MRS at 3T, we examined 47 liver transplantation candidates and 101 liver graft recipients. A point-resolved spectroscopy sequence was used to calculate the steatosis grade along with the saturated, unsaturated and polyunsaturated fractions of fatty acids in the liver. The steatosis grade measured by MRS was compared with the histological steatosis grade. HFC, represented by fat fraction values, is adept at distinguishing non-alcoholic steatohepatitis (NASH), NAFL and non-steatotic liver transplant patients. Relative hepatic lipid saturation increases while unsaturation decreases in response to increased HFC. Additionally, relative hepatic lipid saturation increases while unsaturation and polyunsaturation both decrease in liver recipients with histologically proven post-transplant NASH or NAFL compared to non-steatotic patients. HFC, measured by in vivo 1H MRS, correlated well with histological results. 1H MRS is a simple and fast method for in vivo analysis of HFC and its composition. It provides non-invasive support for NAFL and NASH diagnoses.
- 30 August 2018
- Published by Care Comm in Gastroenterologie a hepatologie
- No. 4,p. 287-292
Alveolar echinococcis – a rare disease requiring a multidisciplinary approach
- 30 August 2018
- Published by Care Comm in Gastroenterologie a hepatologie
- No. 4,p. 287-292
Alveolar echinococcis – a rare disease requiring a multidisciplinary approach
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S18
Acute pancreatitis in liver transplant recipients: incidence and outcome
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S18
Acute pancreatitis in liver transplant recipients: incidence and outcome
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e261
Transcriptomic profiling of transplanted hepatic grafts in relation to non-alcoholic fatty liver disease
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e261
Transcriptomic profiling of transplanted hepatic grafts in relation to non-alcoholic fatty liver disease
- 1 June 2017
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101 (6S2) , S138
Short Term Results of Intestinal Transplantation in Czech Republic
- 1 June 2017
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101 (6S2) , S138
Short Term Results of Intestinal Transplantation in Czech Republic
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1122
Risk of Late-Onset CMV Infection After Liver Transplantation is Associated with Recipient's IFNL4 RS12979860 Genotype
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1122
Risk of Late-Onset CMV Infection After Liver Transplantation is Associated with Recipient's IFNL4 RS12979860 Genotype
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1072
Sa1574 Risk Factors for Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1072
Sa1574 Risk Factors for Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S508
Su1376 Pancreatic Cystic Lesions in Liver Transplant Recipients: Prevalence and Outcome
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S508
Su1376 Pancreatic Cystic Lesions in Liver Transplant Recipients: Prevalence and Outcome
- Open Access
- 28 December 2015
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 22 (5) , 644-655
Prevalence and risk factors of steatosis after liver transplantation and patient outcomes
Steatosis occurs frequently after liver transplantation (LT). We aimed to determine the prevalence of steatosis in adult LT recipients, to determine the effects of significant (>33%; grades 2‐3) steatosis on patient survival, and to identify risk factors for the development of significant steatosis and its effect on fibrosis progression. We retrospectively examined 2360 posttransplant biopsies of 548 LT recipients. Survival was compared between patients with significant steatosis and those with grades 0‐1 steatosis. Patients with significant steatosis were compared to controls without steatosis (grade 0) for clinical and laboratory factors and fibrosis progression. Steatosis was found in 309 (56.4%) patients, including 93 (17.0%) patients with significant steatosis. Steatohepatitis (nonalcoholic fatty liver disease activity score ≥ 5) was diagnosed in 57 (10.4%) patients. The prevalence of steatosis increased from 30.3% at 1 year to 47.6% at 10 years after LT (P < 0.001). Survival times did not differ between groups (P = 0.29). On multivariate analysis of pretransplant factors and initial immunosuppression (IS), alcohol‐induced cirrhosis (P < 0.001) and high body mass index (BMI; P = 0.002) were associated with the development of significant steatosis, whereas increased levels of alkaline phosphatase (P = 0.01) and mycophenolate mofetil given initially (P = 0.009) appeared to protect against significant steatosis. On multivariate analysis of posttransplant factors, high BMI (P < 0.001), serum triglycerides (P < 0.001), alcohol consumption (P = 0.005), and type 2 diabetes mellitus (P = 0.048) were associated with significant steatosis, whereas high creatinine (P = 0.02) appeared to protect against significant steatosis. Significant steatosis was not associated with a higher fibrosis stage (P = 0.62). Posttransplant steatosis affects 56.4% of LT recipients, and the prevalence increases with time after LT. Recipient factors and types of IS affect the risk for significant steatosis, which is not associated with a higher fibrosis stage or worse patient survival. Liver Transplantation 22 644‐655 2016 AASLD.
- 28 December 2015
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 22 (5) , 644-655
Open AccessPrevalence and risk factors of steatosis after liver transplantation and patient outcomes
Steatosis occurs frequently after liver transplantation (LT). We aimed to determine the prevalence of steatosis in adult LT recipients, to determine the effects of significant (>33%; grades 2‐3) steatosis on patient survival, and to identify risk factors for the development of significant steatosis and its effect on fibrosis progression. We retrospectively examined 2360 posttransplant biopsies of 548 LT recipients. Survival was compared between patients with significant steatosis and those with grades 0‐1 steatosis. Patients with significant steatosis were compared to controls without steatosis (grade 0) for clinical and laboratory factors and fibrosis progression. Steatosis was found in 309 (56.4%) patients, including 93 (17.0%) patients with significant steatosis. Steatohepatitis (nonalcoholic fatty liver disease activity score ≥ 5) was diagnosed in 57 (10.4%) patients. The prevalence of steatosis increased from 30.3% at 1 year to 47.6% at 10 years after LT (P < 0.001). Survival times did not differ between groups (P = 0.29). On multivariate analysis of pretransplant factors and initial immunosuppression (IS), alcohol‐induced cirrhosis (P < 0.001) and high body mass index (BMI; P = 0.002) were associated with the development of significant steatosis, whereas increased levels of alkaline phosphatase (P = 0.01) and mycophenolate mofetil given initially (P = 0.009) appeared to protect against significant steatosis. On multivariate analysis of posttransplant factors, high BMI (P < 0.001), serum triglycerides (P < 0.001), alcohol consumption (P = 0.005), and type 2 diabetes mellitus (P = 0.048) were associated with significant steatosis, whereas high creatinine (P = 0.02) appeared to protect against significant steatosis. Significant steatosis was not associated with a higher fibrosis stage (P = 0.62). Posttransplant steatosis affects 56.4% of LT recipients, and the prevalence increases with time after LT. Recipient factors and types of IS affect the risk for significant steatosis, which is not associated with a higher fibrosis stage or worse patient survival. Liver Transplantation 22 644‐655 2016 AASLD.